

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS IX LLC,
Petitioner.

BRISTOL-MYERS SQUIBB PHARMA COMPANY
Patent Owner

Case No.: IPR2015-01723
Patent No. 6,967,208

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES
THEREOF AS FACTOR XA

**PETITIONER'S UPDATED MANDATORY
NOTICE PURSUANT TO 37 C.F.R. § 42.8**

I. Introduction

Petitioner Coalition for Affordable Drugs IX LLC (“CFAD IX”) respectfully submits this Updated Mandatory Notice Pursuant to 37 C.F.R. 42.8(a)(3) and (b)(1). On December 31, 2015 the ownership of CFAD IX changed from being solely owned by Hayman Credes Master Fund, L.P. (“Credes”) to being jointly owned by Credes, Hayman Orange Fund SPC-Portfolio A (“HOF”) and Hayman Capital Master Fund, L.P. (“HCMF”). All of these entities were set forth in the original Mandatory Notices, therefore there have been no additions to, or deletions of, any of the entities originally named as real parties in interest.

II. 37 C.F.R. 42.8(b)(1) Real party-in-interest

Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies that Coalition For Affordable Drugs IX LLC (“CFAD IX”), Hayman Credes Master Fund, L.P. (“Credes”), Hayman Orange Fund SPC – Portfolio A (“HOF”), Hayman Capital Master Fund, L.P. (“HCMF”), Hayman Capital Management, L.P. (“HCM”), Hayman Offshore Management, Inc. (“HOM”), Hayman Investments, L.L.C. (“HI”), nXn Partners, LLC (“nXnP”), IP Navigation Group, LLC (“IPNav”), J. Kyle Bass, and Erich Spangenberg are the real parties in interest (collectively, “RPI”). The RPI

hereby certify the following information: CFAD IX is a jointly owned by Credes, HCMF and HOF. Credes is a limited partnership. HOF is a segregated portfolio company. HCMF is a limited partnership. HCM is the general partner and investment manager of Credes and HCMF. HCM is the investment manager of HOF. HOM is the administrative general partner of Credes and HCMF. HI is the general partner of HCM. J. Kyle Bass is the sole member of HI and sole shareholder of HOM. CFAD IX, Credes, HOF and HCMF act, directly or indirectly, through HCM as the general partner and/or investment manager of Credes, HOF and HCMF. nXnP is a paid consultant to HCM. Erich Spangenberg is the Manager and majority member of nXnP. IPNav is a paid consultant to nXnP. Erich Spangenberg is the Manager and majority member of IPNav. Other than HCM and J. Kyle Bass in his capacity as the Chief Investment Officer of HCM and nXnP and Erich Spangenberg in his capacity as the Manager/CEO of nXnP, no other person (including any investor, limited partner, or member or any other person in any of CFAD IX, Credes, HOF, HCMF, HCM, HOM, HI, nXnP or IPNav) has authority to direct or control (i) the timing of, filing of, content of, or any decisions or other activities relating to this Petition or (ii) any timing, future filings, content of, or any decisions or other activities relating to the future proceedings

related to this Petition. All of the costs associated with this Petition will be borne by HCM, CFAD IX, Credes, HOF and/or HCMF.

Respectfully submitted,

/s/ Thomas C. Wright

Thomas C. Wright
Reg. No. 47189
Cunningham Swaim, LLP
7557 Rambler Road, Suite 440
Dallas, Texas 75231
Telephone: 214-646-1495
Direct: 469-729-7010
Facsimile: 214-613-1163
twright@cunninghamswaim.com

CERTIFICATE OF SERVICE

I certify that, on January 20, 2016, I caused a true and correct copy of the foregoing to be served via electronic mail to counsel for the Patent Owner, Heather Petruzzi and David Cavanaugh.

/s/ Thomas C. Wright

Thomas C. Wright
Reg. No. 47189
Cunningham Swaim, LLP
7557 Rambler Road, Suite 440
Dallas, Texas 75231
Telephone: 214-646-1495
Direct: 469-729-7010
Facsimile: 214-613-1163
twright@cunninghamswaim.com